Skip to main content
Sandra Zeidler and Dr. Christine Wuebben (from left to right) from Bonn at the Pitch4Med Contest at the Heinrich Heine University Düsseldorf

Honors & Funding

ImmunoSensation entrepreneurs successfully pitch an innovative approach to fight respiratory viruses with an immunostimulatory nasal spray

A team of researchers in the group of Gunther Hartmann at the Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, and the Cluster of Excellence ImmunoSensation2 successfully pitched their start-up idea of Coldex, a nasal spray that provides protection from viral infections, at the Pitch4Med Contest at the Heinrich Heine University Düsseldorf and the 2nd Medical Pitch Contest of the Medical Faculty, University of Bonn. 

At the Pitch4Med Contest in Düsseldorf in October 2023, Dr. Christine Wuebben and her co-entrepreneurs first presented their innovative idea in a ten-minute pitch in front of a top-class jury consisting of Dr. Jan Engels, Investment Manager High-Tech Gründerfonds, Rolf Fellmann, Chairman of the business angel network Angel Engine and Lars Gussen, Investment Manager TechVision Fond, who gave the young researchers valuable feedback.

The Coldex team then entered the 2nd Medical Pitch Contest during the MIB Future Panel at the Medical Faculty Bonn with a refined five-minutes pitch. The distinguished jury, consisting of Dr. Laura Pedroza (Investment Manager, Hightech Gründerfonds), Dr. Christopher Jahn (Investment Manager, TechVision Fonds), Maximilian Erb (VC Department, NRW.Bank) and Dr. Alexander Zink (Head of Technology & Innovation, Xlife Sciences) was convinced by the innovative concept and awarded Coldex the shared first place in the competition.

Thanks to its promising approach, the Coldex team recently received prototyping grants from the transfer center enacom of the University of Bonn.

Related news

Precise Konsortium

Publication Honors & Funding

Making Cancer Cells More Predictable: PRECISE Aims to Forecast Therapeutically Actionable Vulnerabilities

—Which genes and signaling pathways does a cancer cell require to survive? And which of these could serve as therapeutic targets? The pan-European initiative PRECISE aims to identify such vulnerabilities not only through labor-intensive laboratory experiments but also by predicting them using computational models. The UKB and the University of Bonn, represented by Prof. Dr. Maximilian Billmann and Prof. Dr. Jonathan Schmid-Burgk, are among the founding partners of the consortium. The scientific vision of the initiative has now been published in a commentary in Nature Genetics.
View entry
Prof. Dr. Jörg Wenzel

Honors & Funding

Jörg Wenzel elected chair of EADV Task Force on Cutaneous Lupus Erythematosus (CLE)

—The European Academy of Dermatology and Venereology (EADV) has establishment a new Task Force on Cutaneous Lupus Erythematosus (CLE), led by ImmunoSensation³ member Jörg Wenzel. CLE, as autoimmune disease of the skin, is a prime example of chronic inflammatory dysregulation, leading to a severe disease burden. The treatment of cutaneous lupus continues to face unresolved clinical challenges. The CLE Task Force is set up to push the boundaries of clinical care, update guidelines, and advance collaborative research across Europe.
EADV Task Forces
News Marvin Supercomputer

Honors & Funding

Two years of the Marvin Supercomputer: Researchers in Bonn present their projects

—Two years after it went into operation, the University of Bonn celebrated the Marvin Supercomputer with a community event at the Research and Technology Center for Detector Physics (FTD). Researchers from various disciplines presented projects that had been carried out using high-performance computing and used the event as an opportunity for interdisciplinary exchange. A team lead by ImmunoSensation³ members Prof. Dr. Michael Hölzel (Institute of Experimental Oncology) and PD Dr. Gregor Hagelueken (Institute of Structural Biology) use Marvin to design new proteins.
View entry

Back to the news overview